Adaptive Biotechnologies Corporation (MUN:1HM)
Germany · Delayed Price · Currency is EUR | Market Cap | 3.43B +109.1% |
| Revenue (ttm) | 269.66M +50.1% |
| Net Income | -55.89M |
| EPS | -0.36 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 21.10 |
| Previous Close | 20.63 |
| Day's Range | 21.10 - 21.10 |
| 52-Week Range | 12.84 - 21.10 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minima... [Read more]
Financial Performance
In 2025, Adaptive Biotechnologies's revenue was $276.98 million, an increase of 54.77% compared to the previous year's $178.96 million. Losses were -$59.50 million, -62.69% less than in 2024.
Financial numbers in USD Financial StatementsNews
Adaptive Biotechnologies Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
NCCN guidelines now specifically name clonoSEQ for MRD testing in multiple myeloma, boosting clinical adoption and expanding the addressable market. Strong volume growth, increased use of blood-based testing, and robust pharma momentum support a positive financial outlook, while a planned business separation aims to unlock further value.
Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune sys...
Adaptive Biotech co-founder raises $15M for new startup to rethink how AI trains on science
Harlan Robins spent years as the co-founder and chief scientific officer of Adaptive Biotechnologies, helping build massive datasets to decode
Adaptive Biotechnologies price target raised to $27.50 from $20 at Piper Sandler
Piper Sandler raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $27.50 from $20 following quarterly results. The firm keeps an Overweight rating on the shares. Published first on…
Adaptive Biotechnologies price target raised to $27 from $25 at JPMorgan
JPMorgan raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $27 from $25 and keeps an Overweight rating on the shares.
Adaptive Biotechnologies price target raised to $22 from $20 at Morgan Stanley
Morgan Stanley analyst Kallum Titchmarsh raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $22 from $20 and keeps an Equal Weight rating on the shares. Adaptive “exceeded the…
Adaptive Biotechnologies price target raised to $25 from $24 at BTIG
BTIG raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $25 from $24 and keeps a Buy rating on the shares. The company delivered another strong beat and raise…
Adaptive Biotechnologies price target raised to $28 from $25 at TD Cowen
TD Cowen raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $28 from $25 and keeps a Buy rating on the shares. The firm said they delivered another solid…
Adaptive Biotechnologies price target raised to $25 from $22 at Guggenheim
Guggenheim raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $25 from $22 and keeps a Buy rating on the shares after Adaptive “beat again” on volumes. Even with…
Adaptive Biotechnologies reports Q2 EPS (25c), consensus (13c)
Reports Q2 revenue $71.6M, consensus $65.45M. Cash, cash equivalents and marketable securities was $371.7M as of June 30, inclusive of $15.1M of cash and cash equivalents held by Digital Biotechnologi...
Adaptive Biotechnologies sees FY26 revenue $268M-$278M from MRD business
No revenue guidance was provided for the Immune Medicine business. The company expects FY26 total company operating expenses, including cost of revenue, to be between $350M-$355M, updated from the pre...
Adaptive Biotechnologies Earnings Call Transcript: Q2 2026
Q2 saw robust MRD revenue and volume growth, margin expansion, and a strengthened balance sheet. Guidance was raised for MRD revenue and clinical volume, with continued momentum in both clinical and pharma segments. The company is progressing on the separation of its Immune Medicine business.
Adaptive Biotechnologies Earnings release: Q2 2026
Adaptive Biotechnologies released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Adaptive Biotechnologies Slides: Q2 2026
Adaptive Biotechnologies has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.
Adaptive Biotechnologies Quarterly report: Q2 2026
Adaptive Biotechnologies has published its Q2 2026 quarterly earnings report on July 29, 2026.
Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results
SEATTLE, July 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetic...
Adaptive Biotechnologies price target raised to $25 from $21 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $25 from $21 and keeps a Buy rating on the shares. The firm adjusted targets…
Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026
SEATTLE, July 09, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst...
Adaptive Biotechnologies price target raised to $20 from $18 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $20 from $18 and keeps an Equal Weight rating on the shares. The firm is updating its model…
Adaptive Biotechnologies price target raised to $22 from $21 at Guggenheim
Guggenheim raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $22 from $21 and keeps a Buy rating on the shares. The firm adjusted models and forecasts for select…
Adaptive Biotechnologies prices $300M convertible senior note offering
Adaptive Biotechnologies (ADPT) “announced the pricing of its offering of $300 million aggregate principal amount of 0% convertible senior notes due 2031 in a private offering to persons reasonably be...
Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering
Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibility Additional proceeds used to pay for the capped call with a premium of 100% and to repurchase $...
Adaptive Biotechnologies management to meet with Craig-Hallum
Meeting to be held in New York on June 18 hosted by Craig-Hallum.
Adaptive Biotechnologies offers to sell $250M in 2031 convertible senior notes
Last night, the company stated: “Adaptive Biotechnologies (ADPT) announced its intention to offer, subject to market and other conditions, $250 million aggregate principal amount of convertible senior...
Adaptive Biotechnologies plans separation of immune medicine platform
Adaptive Biotechnologies said on Monday it planned to separate its immune medicine business from its residual cancer-testing unit, as it reviews options for the drug-discovery business and focuses o...